Natural-derived drug carriers (NDDCs) for precision therapy
1 School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China
2 School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China
3 Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China
|
HE Wei: Dr. Wei He is a professor at the College of Pharmaceutical Science, China Pharmaceutical University (since July 2012). He obtained his Ph.D. from Fudan University, worked as a project leader in CSPC Pharmaceutical Co., Ltd. from 2007 to 2009, as a researcher at Alberta University (Canada) and as a visiting scholar at Harvard University from November 2018 to October 2019. His current research mainly includes biopharmaceutical delivery and vascular-targeted drug delivery. He is the editorial board member of Chinese Chemical Letters, Pharmaceutics and Acta Pharmaceutica Sinica B and the guest editor of Acta Pharmaceutica Sinica B and Advanced Drug Delivery Reviews. He has published more than 100 papers, with 7 highly cited papers；
|
|
HE Wei: Dr. Wei He is a professor at the College of Pharmaceutical Science, China Pharmaceutical University (since July 2012). He obtained his Ph.D. from Fudan University, worked as a project leader in CSPC Pharmaceutical Co., Ltd. from 2007 to 2009, as a researcher at Alberta University (Canada) and as a visiting scholar at Harvard University from November 2018 to October 2019. His current research mainly includes biopharmaceutical delivery and vascular-targeted drug delivery. He is the editorial board member of Chinese Chemical Letters, Pharmaceutics and Acta Pharmaceutica Sinica B and the guest editor of Acta Pharmaceutica Sinica B and Advanced Drug Delivery Reviews. He has published more than 100 papers, with 7 highly cited papers；SHI Yujie: Dr. Yujie Shi is a lecturer at School of Pharmaceutical Sciences, Peking University (since August 2005). She graduated from China Pharmaceutical University and obtained her Ph.D. degree from Peking University, worked as a visiting scholar at Harvard University from July 2018 to July 2020. She is the editorial board member of Chinese Chemical Letters. She is currently focused on developing innovative strategies to overcome the challenges associated with the oral bioavailability of hydrophobic small-molecule therapeutics and macromolecules. She has published over 30 research papers in journals, including Advanced Science, Journal of Controlled Release, Advanced Healthcare Materials, Acta Pharmaceutica Sinica B, and Chinese Chemical Letters；
|
|
HQU Ding: Dr. Ding Qu is a professor at the Jiangsu Academy of Chinese Medicine (Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine). Qu obtained his Ph.D. from China Pharmaceutical University, and was a senior visiting scholar at the University of Massachusetts Medical School (USA) from August 2019 to September 2020. His current leading research includes traditional Chinese medicine-based drug delivery systems for various tumor- and inflammation-related disease therapies. He is a young editorial board member of Acupuncture and Herbal Medicines, Chinese Traditional and Herbal Drugs, Chinese Journal of Hospital Pharmacy, and Brain-X (contributing editor). He has published more than 60 papers, with more than 1000 citations.
|
Show less
PDF
(3357KB)
